Skip to main content
Erschienen in:

07.03.2022 | Herzinsuffizienz | CME

Erhalt von Leistungsfähigkeit und Lebensqualität bei chronischer Herzinsuffizienz

Teil 1 – Arzneimitteltherapie

verfasst von: Prof. Dr. Dr. med. Stephan von Haehling, Michael Arzt, Wolfram Doehner, Frank Edelmann, Ruben Evertz, Nicole Ebner, Christoph Herrmann-Lingen, Tania Garfias-Veitl, Michael Koziolek, Michel Noutsias, P. Christian Schulze, Rolf Wachter, Gerd Hasenfuß, Ulrich Laufs

Erschienen in: Die Kardiologie | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Endpunkte großer klinischer Studien in der Herzinsuffizienz umfassen meist die Zahl der Krankenhausaufnahmen und die kardiovaskuläre Mortalität. Patienten mit Herzinsuffizienz leiden jedoch auch an einer Abnahme der körperlichen Belastbarkeit und der Lebensqualität. Das Ziel dieses 3‑teiligen Übersichtsbeitrags ist es, anhand der Aspekte leitliniengerechte Arzneimitteltherapie, Behandlung von Komorbiditäten und des körperlichen Trainings Möglichkeiten aufzuzeigen, die zum Erhalt der Mobilität und der Lebensqualität bei Patienten mit Herzinsuffizienz geeignet sind. Im hier vorliegenden ersten Teil zeigen wir, dass Studien zu Ivabradin, SGLT2(Natrium-Glukose-Co-Transporter 2)-Inhibitoren und Sacubitril/Valsartan eine Verbesserung der Lebensqualität in der Therapie der Herzinsuffizienz mit reduzierter Pumpfunktion andeuten. Die Daten zur Herzinsuffizienz mit erhaltener Pumpfunktion sind bis auf erste Daten zu Lebensqualität und Empagliflozin wenig überzeugend. Zusätzliche Studien zur Funktionsfähigkeit und Lebensqualität bei Herzinsuffizienz sind nötig.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K, Filippatos G (2014) Heart failure: preventing disease and death worldwide. ESC Heart Fail 1:4–25PubMedCrossRef Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K, Filippatos G (2014) Heart failure: preventing disease and death worldwide. ESC Heart Fail 1:4–25PubMedCrossRef
2.
Zurück zum Zitat McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli FM, Price S, Rosano GMC, Ruschitzka F, Skibelund KA, ESC Scientific Document Group (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726PubMedCrossRef McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli FM, Price S, Rosano GMC, Ruschitzka F, Skibelund KA, ESC Scientific Document Group (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726PubMedCrossRef
3.
Zurück zum Zitat Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, Witteman JC, Stricker BH (2004) Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 25:1614–1619PubMedCrossRef Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, Witteman JC, Stricker BH (2004) Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 25:1614–1619PubMedCrossRef
4.
Zurück zum Zitat Christ M, Störk S, Dörr M, Heppner HJ, Müller C, Wachter R, Riemer U, Germany Project THF (2016) Heart failure epidemiology 2000–2013: insights from the German Federal Health Monitoring System. Eur J Heart Fail 18:1009–1018PubMedCrossRef Christ M, Störk S, Dörr M, Heppner HJ, Müller C, Wachter R, Riemer U, Germany Project THF (2016) Heart failure epidemiology 2000–2013: insights from the German Federal Health Monitoring System. Eur J Heart Fail 18:1009–1018PubMedCrossRef
5.
Zurück zum Zitat Lavine KJ, Mann DL (2013) Rethinking phase II clinical trial design in heart failure. Clin Investig 3:57–68CrossRef Lavine KJ, Mann DL (2013) Rethinking phase II clinical trial design in heart failure. Clin Investig 3:57–68CrossRef
6.
Zurück zum Zitat Luo N, O’Connor CM, Cooper LB, Sun JL, Coles A, Reed SD, Whellan DJ, Piña IL, Kraus WE, Mentz RJ (2019) Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION. Eur J Heart Fail 21:63–70PubMedCrossRef Luo N, O’Connor CM, Cooper LB, Sun JL, Coles A, Reed SD, Whellan DJ, Piña IL, Kraus WE, Mentz RJ (2019) Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION. Eur J Heart Fail 21:63–70PubMedCrossRef
7.
9.
Zurück zum Zitat von Haehling S, Arzt M, Doehner W, Edelmann F, Evertz R, Ebner N, Herrmann-Lingen C, Garfias Macedo T, Koziolek M, Noutsias M, Schulze PC, Wachter R, Hasenfuß G, Laufs U (2021) Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials. Eur J Heart Fail 23:92–113CrossRef von Haehling S, Arzt M, Doehner W, Edelmann F, Evertz R, Ebner N, Herrmann-Lingen C, Garfias Macedo T, Koziolek M, Noutsias M, Schulze PC, Wachter R, Hasenfuß G, Laufs U (2021) Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials. Eur J Heart Fail 23:92–113CrossRef
10.
Zurück zum Zitat Garin O, Herdman M, Vilagut G, Ferrer M, Ribera A, Rajmil L, Valderas JM, Guillemin F, Revicki D, Alonso J (2014) Assessing health-related quality of life in patients with heart failure: a systematic, standardized comparison of available measures. Heart Fail Rev 19:359–367PubMedCrossRef Garin O, Herdman M, Vilagut G, Ferrer M, Ribera A, Rajmil L, Valderas JM, Guillemin F, Revicki D, Alonso J (2014) Assessing health-related quality of life in patients with heart failure: a systematic, standardized comparison of available measures. Heart Fail Rev 19:359–367PubMedCrossRef
11.
Zurück zum Zitat Täger T, Hanholz W, Cebola R, Fröhlich H, Franke J, Doesch A, Katus HA, Wians FH Jr, Frankenstein L (2014) Minimal important difference for 6‑minute walk test distances among patients with chronic heart failure. Int J Cardiol 176:94–98PubMedCrossRef Täger T, Hanholz W, Cebola R, Fröhlich H, Franke J, Doesch A, Katus HA, Wians FH Jr, Frankenstein L (2014) Minimal important difference for 6‑minute walk test distances among patients with chronic heart failure. Int J Cardiol 176:94–98PubMedCrossRef
12.
Zurück zum Zitat O’Meara E, Solomon S, McMurray J, Pfeffer M, Yusuf S, Michelson E, Granger C, Olofsson B, Young JB, Swedberg K (2004) Effect of candesartan on New York heart association functional class. Results of the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J 25:1920–1926PubMedCrossRef O’Meara E, Solomon S, McMurray J, Pfeffer M, Yusuf S, Michelson E, Granger C, Olofsson B, Young JB, Swedberg K (2004) Effect of candesartan on New York heart association functional class. Results of the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J 25:1920–1926PubMedCrossRef
13.
Zurück zum Zitat Riegger GA, Bouzo H, Petr P, Münz J, Spacek R, Pethig H, von Behren V, George M, Arens H (1999) Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Circulation 100:2224–2230PubMedCrossRef Riegger GA, Bouzo H, Petr P, Münz J, Spacek R, Pethig H, von Behren V, George M, Arens H (1999) Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Circulation 100:2224–2230PubMedCrossRef
14.
Zurück zum Zitat Ariti CA, Cleland JG, Pocock SJ, Pfeffer MA, Swedberg K, Granger CB, McMurray JJ, Michelson EL, Ostergren J, Yusuf S (2011) Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J 162:900–906PubMedCrossRef Ariti CA, Cleland JG, Pocock SJ, Pfeffer MA, Swedberg K, Granger CB, McMurray JJ, Michelson EL, Ostergren J, Yusuf S (2011) Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J 162:900–906PubMedCrossRef
15.
Zurück zum Zitat Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, PEP-CHF Investigators (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27:2338–2345PubMedCrossRef Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, PEP-CHF Investigators (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27:2338–2345PubMedCrossRef
16.
Zurück zum Zitat Stock JP (1966) Beta adrenergic blocking drugs in the clinical management of cardiac arrhythmias. Am J Cardiol 18:444–449PubMedCrossRef Stock JP (1966) Beta adrenergic blocking drugs in the clinical management of cardiac arrhythmias. Am J Cardiol 18:444–449PubMedCrossRef
17.
Zurück zum Zitat Funck-Brentano C (2006) Beta-blockade in CHF: from contraindication to indication. Eur Heart J Suppl 8:C19–C27CrossRef Funck-Brentano C (2006) Beta-blockade in CHF: from contraindication to indication. Eur Heart J Suppl 8:C19–C27CrossRef
18.
Zurück zum Zitat Conraads VM, Metra M, Kamp O, De Keulenaer GW, Pieske B, Zamorano J, Vardas PE, Böhm M, Dei CL (2012) Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 14:219–225PubMedCrossRef Conraads VM, Metra M, Kamp O, De Keulenaer GW, Pieske B, Zamorano J, Vardas PE, Böhm M, Dei CL (2012) Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 14:219–225PubMedCrossRef
19.
Zurück zum Zitat Vilaine JP (2006) The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease. Pharmacol Res 53:424–434PubMedCrossRef Vilaine JP (2006) The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease. Pharmacol Res 53:424–434PubMedCrossRef
20.
Zurück zum Zitat Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376:886–894PubMedCrossRef Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376:886–894PubMedCrossRef
21.
Zurück zum Zitat Ekman I, Chassany O, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 32:2395–2404PubMedCrossRef Ekman I, Chassany O, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 32:2395–2404PubMedCrossRef
22.
Zurück zum Zitat Volterrani M, Cice G, Caminiti G, Vitale C, D’Isa S, Perrone Filardi P, Acquistapace F, Marazzi G, Fini M, Rosano GM (2011) Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol 151:218–224PubMedCrossRef Volterrani M, Cice G, Caminiti G, Vitale C, D’Isa S, Perrone Filardi P, Acquistapace F, Marazzi G, Fini M, Rosano GM (2011) Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol 151:218–224PubMedCrossRef
23.
Zurück zum Zitat Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikowski P, Voors AA, Dominjon F, Henon-Goburdhun C, Pannaux M, Böhm M, prEserveD left ventricular ejection fraction chronic heart Failure with ivabradine studY (EDIFY) Investigators (2017) Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebocontrolled trial. Eur J Heart Fail 19:1495–1503PubMedCrossRef Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikowski P, Voors AA, Dominjon F, Henon-Goburdhun C, Pannaux M, Böhm M, prEserveD left ventricular ejection fraction chronic heart Failure with ivabradine studY (EDIFY) Investigators (2017) Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebocontrolled trial. Eur J Heart Fail 19:1495–1503PubMedCrossRef
24.
Zurück zum Zitat McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004PubMedCrossRef McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004PubMedCrossRef
25.
Zurück zum Zitat Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Saraiva KJF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, PARAGON-HF Investigators and Committees (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. https://doi.org/10.1056/NEJMoa1908655PubMedCrossRef Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Saraiva KJF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, PARAGON-HF Investigators and Committees (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. https://​doi.​org/​10.​1056/​NEJMoa1908655PubMedCrossRef
26.
Zurück zum Zitat Piepoli MF, Hussain RI, Comin-Colet J, Dosantos R, Ferber P, Jaarsma T, Edelmann F (2021) OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. Eur J Heart Fail 23:127–135. https://doi.org/10.1002/ejhf.2076PubMedCrossRef Piepoli MF, Hussain RI, Comin-Colet J, Dosantos R, Ferber P, Jaarsma T, Edelmann F (2021) OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. Eur J Heart Fail 23:127–135. https://​doi.​org/​10.​1002/​ejhf.​2076PubMedCrossRef
27.
Zurück zum Zitat Rodrigues Dos Santos M, Alves MNN, Jordão CP, Pinto CEN, Correa KTS, de Souza FR, da Fonseca GWP, Filho JT, Costa M, Pereira RMR, Negrão CE, Barretto ACP (2021) Sacubitril/Valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: a randomized, double-blind, active-controlled study: Sacubitril/Valsartan and Enalapril on peak VO2 in patients with heart failure with reduced ejection fraction. Am Heart J. https://doi.org/10.1016/j.ahj.2021.05.005CrossRef Rodrigues Dos Santos M, Alves MNN, Jordão CP, Pinto CEN, Correa KTS, de Souza FR, da Fonseca GWP, Filho JT, Costa M, Pereira RMR, Negrão CE, Barretto ACP (2021) Sacubitril/Valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: a randomized, double-blind, active-controlled study: Sacubitril/Valsartan and Enalapril on peak VO2 in patients with heart failure with reduced ejection fraction. Am Heart J. https://​doi.​org/​10.​1016/​j.​ahj.​2021.​05.​005CrossRef
28.
Zurück zum Zitat Khandwalla RM, Grant D, Birkeland K, Heywood JT, Fombu E, Owens RL, Steinhubl SR, AWAKE‑H. F (2021) Study Investigators The AWAKE-HF study: sacubitril/valsartan impact on daily physical activity and sleep in heart failure. Am J Cardiovasc Drugs 21:241–254. https://doi.org/10.1007/s40256-020-00440-y Khandwalla RM, Grant D, Birkeland K, Heywood JT, Fombu E, Owens RL, Steinhubl SR, AWAKE‑H. F (2021) Study Investigators The AWAKE-HF study: sacubitril/valsartan impact on daily physical activity and sleep in heart failure. Am J Cardiovasc Drugs 21:241–254. https://​doi.​org/​10.​1007/​s40256-020-00440-y
29.
Zurück zum Zitat Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717PubMedCrossRef Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717PubMedCrossRef
30.
Zurück zum Zitat Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, Group E‑HS (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21PubMedCrossRef Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, Group E‑HS (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21PubMedCrossRef
31.
Zurück zum Zitat Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Marino P, Zardini P (2002) Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 40:304–310PubMedCrossRef Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Marino P, Zardini P (2002) Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 40:304–310PubMedCrossRef
32.
Zurück zum Zitat Lewis EF, Kim HY, Claggett B, Spertus J, Heitner JF, Assmann SF, Kenwood CT, Solomon SD, Desai AS, Fang JC, McKinlay SA, Pitt BA, Pfeffer MA, Investigators T (2016) Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an Aldosterone antagonist trial. Circ Heart Fail 9:e1937PubMedCrossRef Lewis EF, Kim HY, Claggett B, Spertus J, Heitner JF, Assmann SF, Kenwood CT, Solomon SD, Desai AS, Fang JC, McKinlay SA, Pitt BA, Pfeffer MA, Investigators T (2016) Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an Aldosterone antagonist trial. Circ Heart Fail 9:e1937PubMedCrossRef
33.
Zurück zum Zitat Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Loffler M, Dungen HD, Tschope C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B, Aldo DHFI (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309:781–791PubMedCrossRef Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Loffler M, Dungen HD, Tschope C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B, Aldo DHFI (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309:781–791PubMedCrossRef
34.
Zurück zum Zitat Ravassa S, Trippel T, Bach D et al (2018) Biomarker-based phenotyping of myocardial ibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. Eur J Heart Fail 20:1290–1299PubMedCrossRef Ravassa S, Trippel T, Bach D et al (2018) Biomarker-based phenotyping of myocardial ibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. Eur J Heart Fail 20:1290–1299PubMedCrossRef
35.
Zurück zum Zitat Kosmala W, Rojek A, Przewlocka-Kosmala M, Wright L, Mysiak A, Marwick TH (2016) Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. J Am Coll Cardiol 68:1823–1834PubMedCrossRef Kosmala W, Rojek A, Przewlocka-Kosmala M, Wright L, Mysiak A, Marwick TH (2016) Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. J Am Coll Cardiol 68:1823–1834PubMedCrossRef
36.
Zurück zum Zitat Li S, Zhang X, Dong M, Gong S, Shang Z, Jia X, Chen W, Yang J, Li J (2018) Effects of spironolactone in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Medicine 97:e11942PubMedPubMedCentralCrossRef Li S, Zhang X, Dong M, Gong S, Shang Z, Jia X, Chen W, Yang J, Li J (2018) Effects of spironolactone in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Medicine 97:e11942PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Fukuta H, Goto T, Wakami K, Kamiya T, Ohte N (2018) Effects of mineralocorticoid receptor antagonists on left ventricular diastolic function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Heart Vessels. https://doi.org/10.1007/s00380-018-1279-1PubMedCrossRef Fukuta H, Goto T, Wakami K, Kamiya T, Ohte N (2018) Effects of mineralocorticoid receptor antagonists on left ventricular diastolic function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Heart Vessels. https://​doi.​org/​10.​1007/​s00380-018-1279-1PubMedCrossRef
38.
Zurück zum Zitat Epstein M, Calhoun DA (2011) Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. Clin Hypertens 13:644–648CrossRef Epstein M, Calhoun DA (2011) Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. Clin Hypertens 13:644–648CrossRef
39.
Zurück zum Zitat Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, Giannetti N, Januzzi JL, Piña IL, Lam CSP, Ponikowski P, Sattar N, Verma S, Brueckmann M, Jamal W, Vedin O, Peil B, Zeller C, Zannad F, Packer M, EMPEROR-Reduced Trial Committees and Investigators (2021) Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J 42:1203–1212PubMedPubMedCentralCrossRef Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, Giannetti N, Januzzi JL, Piña IL, Lam CSP, Ponikowski P, Sattar N, Verma S, Brueckmann M, Jamal W, Vedin O, Peil B, Zeller C, Zannad F, Packer M, EMPEROR-Reduced Trial Committees and Investigators (2021) Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J 42:1203–1212PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Brueckmann M, Jamal W, Zeller C, Schnaidt S, Zannad F (2021) Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Circulation 143:326–336PubMedCrossRef Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Brueckmann M, Jamal W, Zeller C, Schnaidt S, Zannad F (2021) Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Circulation 143:326–336PubMedCrossRef
41.
Zurück zum Zitat Butler J, Filippatos G, Siddiqi JT, Brueckmann M, Böhm M, Chopra VK, Ferreira PJ, Januzzi JL, Kaul S, Piña IL, Ponikowski P, Shah SJ, Senni M, Vedin O, Verma S, Peil B, Pocock SJ, Zannad F, Packer M, Anker SD (2022) Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-preserved trial. Circulation 145(3):184–193. https://doi.org/10.1161/CIRCULATIONAHA.121.057812PubMedCrossRef Butler J, Filippatos G, Siddiqi JT, Brueckmann M, Böhm M, Chopra VK, Ferreira PJ, Januzzi JL, Kaul S, Piña IL, Ponikowski P, Shah SJ, Senni M, Vedin O, Verma S, Peil B, Pocock SJ, Zannad F, Packer M, Anker SD (2022) Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-preserved trial. Circulation 145(3):184–193. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​121.​057812PubMedCrossRef
Metadaten
Titel
Erhalt von Leistungsfähigkeit und Lebensqualität bei chronischer Herzinsuffizienz
Teil 1 – Arzneimitteltherapie
verfasst von
Prof. Dr. Dr. med. Stephan von Haehling
Michael Arzt
Wolfram Doehner
Frank Edelmann
Ruben Evertz
Nicole Ebner
Christoph Herrmann-Lingen
Tania Garfias-Veitl
Michael Koziolek
Michel Noutsias
P. Christian Schulze
Rolf Wachter
Gerd Hasenfuß
Ulrich Laufs
Publikationsdatum
07.03.2022
Verlag
Springer Medizin
Erschienen in
Die Kardiologie / Ausgabe 2/2022
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI
https://doi.org/10.1007/s12181-022-00537-5

Weitere Artikel der Ausgabe 2/2022

Die Kardiologie 2/2022 Zur Ausgabe